Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
Expert Review of Anticancer Therapy
|
October 18, 2019
Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers
Bridgette Schroader, Sheldon Kong, Sibyl Anderson, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 1, 2022
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma
Kangho Suh, Josh J Carlson, Fang Xia, et al.
Gates Open Research
|
December 16, 2022
Quantifying the economic burden of unintended pregnancies due to drug-drug interactions with hormonal contraceptives from the United States payer perspective
Meenakshi Srinivasan, Annesha White, Jason Lott, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 25, 2020
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Journal of Occupational and Environmental Medicine
|
May 14, 2005
Employees with overactive bladder: work loss burden
Eric Q Wu, Howard Birnbaum, Maryna Marynchenko, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 2, 2024
Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer
Kangho Suh, Ashley Kang, Gilbert Ko, et al.
American Health & Drug Benefits
|
June 20, 2017
Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea
Todd Williamson, Rajesh Kamalakar, Augustina Ogbonnaya, et al.
Journal of Managed Care & Specialty Pharmacy
|
November 30, 2020
THE AUTHORS RESPOND
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Applied Health Economics and Health Policy
|
September 6, 2011
Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
Noam Y Kirson, Howard G Birnbaum, Jasmina I Ivanova, et al.
Applied Health Economics and Health Policy
|
August 31, 2011
Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population
Noam Y Kirson, Howard G Birnbaum, Jasmina I Ivanova, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
Expert Review of Anticancer Therapy
|
October 18, 2019
Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers
Bridgette Schroader, Sheldon Kong, Sibyl Anderson, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 1, 2022
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma
Kangho Suh, Josh J Carlson, Fang Xia, et al.
Gates Open Research
|
December 16, 2022
Quantifying the economic burden of unintended pregnancies due to drug-drug interactions with hormonal contraceptives from the United States payer perspective
Meenakshi Srinivasan, Annesha White, Jason Lott, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 25, 2020
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Journal of Occupational and Environmental Medicine
|
May 14, 2005
Employees with overactive bladder: work loss burden
Eric Q Wu, Howard Birnbaum, Maryna Marynchenko, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 2, 2024
Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer
Kangho Suh, Ashley Kang, Gilbert Ko, et al.
American Health & Drug Benefits
|
June 20, 2017
Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea
Todd Williamson, Rajesh Kamalakar, Augustina Ogbonnaya, et al.
Journal of Managed Care & Specialty Pharmacy
|
November 30, 2020
THE AUTHORS RESPOND
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Applied Health Economics and Health Policy
|
September 6, 2011
Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
Noam Y Kirson, Howard G Birnbaum, Jasmina I Ivanova, et al.
Applied Health Economics and Health Policy
|
August 31, 2011
Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population
Noam Y Kirson, Howard G Birnbaum, Jasmina I Ivanova, et al.
Page
of 4